Literature DB >> 10761561

Renal manifestations associated with hepatitis C virus.

R A Sinico1, A Fornasieri, G D'Amico.   

Abstract

Among the several types of chronic glomerulonephritis (GN) described in association with hepatitis C virus (HCV) infection, cryoglobulinemic glomerulonephritis is by far the most frequent. It is usually associated with type II cryoglobulinemia with IgM k rheumatoid factor. It is a membranoproliferative GN, which shows some distinctive histologic features (intraglomerular monocyte infiltration, intraluminal thrombi due to massive precipitation of cryoglobulins, renal vasculitis), has a chronic course with acute recurrent episodes that can be controlled by corticosteroids more than by antiviral therapy (interferon alpha). More controversial is the association with type I non-cryoglobulinemic membranoproliferative GN, which has been found in some series from the USA and Japan but not in others. The demonstration of HCV antibodies and/or HCV-RNA in other types of chronic glomerulonephritis is usually reported in a small minority of cases suggesting the possibility of a coincidental finding more than an etiologic factor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761561

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


  3 in total

Review 1.  Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

2.  Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice.

Authors:  S Taneda; S Segerer; K L Hudkins; Y Cui; M Wen; M Segerer; M H Wener; C G Khairallah; A G Farr; C E Alpers
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 3.  [Vasculitis associated with viral infections].

Authors:  Pascal Cohen; Loïc Guillevin
Journal:  Presse Med       Date:  2004-11-06       Impact factor: 1.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.